The partnership will give clients increased efficiency and diversity in the drug discovery process.
A new partnership announced today between Charles River Laboratories and Atomwise will offer biotech and pharmaceutical companies an end-to-end discovery solution that brings together artificial intelligence (AI) technology with premium research services.
Charles River provides products and services to help companies accelerate their research and drug development. The partnership will give its clients access to Atomwise’s AI-powered, structure-based, drug design technology that allows scientists to predict how well a small molecule will bind to a target protein of interest.
Atomwise’s technology analyzes billions of compounds and screens challenging target proteins in the small molecule drug discovery process. The AI allows researchers to quickly test a large and diverse chemical space and only focuses on compounds predicted to have improved target-binding attributes.
The partnership will give Charles River’s clients increased efficiency and diversity in the drug discovery process.
“By cutting time out of each stage of the drug discovery process, we enable our clients to deliver novel therapeutics to patients more efficiently and effectively,” said James Foster, president and CEO of Charles River.
Atomwise will support hit discovery, hit-to-lead and lead optimization efforts and will receive technology access fees, milestone-based payments and royalties from clients — a value the company projects could exceed $2.4 billion.
“Through this collaboration, we will bring our technology and experience in drug discovery to more biotech and pharma partners, furthering our mission to discover and develop new medicines for patients,” said Atomwise CEO Abraham Heifets, Ph.D.
Get the best insights in healthcare analytics directly to your inbox.